Atossa Therapeutics Past Earnings Performance
Past criteria checks 0/6
Atossa Therapeutics's earnings have been declining at an average annual rate of -13.7%, while the Biotechs industry saw earnings growing at 19.1% annually.
Key information
-13.7%
Earnings growth rate
56.1%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | -32.3% |
Net Margin | n/a |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth
Jul 01Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans
Mar 07We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Nov 08Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth
Apr 26We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Jan 09Atossa Therapeutics: Still Gets An 'Incomplete' Rating
Oct 11We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely
Sep 25Atossa Therapeutics GAAP EPS of -$0.05
Aug 08Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth
May 12A First Assessment On Atossa Therapeutics
Dec 10We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Dec 02Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World
Sep 22Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business
Jul 17Atossa Therapeutics: Hope Springs Eternal
Jun 30Atossa Therapeutics to be included in the Russell 2000, 3000 indexes
Jun 16Atossa reaches a two-year high ahead of data readout for breast cancer therapy
Jun 07Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans
Apr 02Atossa updates on single-patient study for Endoxifen
Feb 04Atossa halts Endoxifen breast cancer study after positive data
Feb 02Atossa Therapeutics prices ~$25M direct offering, stock -23% PM
Jan 06Atossa Therapeutics prices $14M registered direct offering
Dec 17We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Dec 10Atossa Therapeutics plummets 38% after it raises $20M in public offering
Dec 09Atossa Therapeutics EPS in-line
Nov 13Safety data on COVID-19 nasal spray fails to lift Atossa, down 6%
Nov 10Revenue & Expenses Breakdown
How Atossa Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 0 | -26 | 13 | 17 |
31 Mar 24 | 0 | -30 | 14 | 18 |
31 Dec 23 | 0 | -30 | 14 | 17 |
30 Sep 23 | 0 | -30 | 14 | 17 |
30 Jun 23 | 0 | -32 | 14 | 17 |
31 Mar 23 | 0 | -28 | 13 | 17 |
31 Dec 22 | 0 | -27 | 13 | 15 |
30 Sep 22 | 0 | -24 | 12 | 12 |
30 Jun 22 | 0 | -21 | 12 | 9 |
31 Mar 22 | 0 | -22 | 12 | 9 |
31 Dec 21 | 0 | -21 | 11 | 9 |
30 Sep 21 | 0 | -28 | 10 | 10 |
30 Jun 21 | 0 | -26 | 9 | 9 |
31 Mar 21 | 0 | -23 | 8 | 7 |
31 Dec 20 | 0 | -22 | 8 | 7 |
30 Sep 20 | 0 | -13 | 8 | 5 |
30 Jun 20 | 0 | -13 | 8 | 5 |
31 Mar 20 | 0 | -16 | 10 | 6 |
31 Dec 19 | 0 | -17 | 11 | 7 |
30 Sep 19 | 0 | -17 | 10 | 7 |
30 Jun 19 | 0 | -17 | 10 | 6 |
31 Mar 19 | 0 | -25 | 8 | 5 |
31 Dec 18 | 0 | -23 | 7 | 4 |
30 Sep 18 | 0 | -23 | 7 | 4 |
30 Jun 18 | 0 | -22 | 7 | 3 |
31 Mar 18 | 0 | -11 | 5 | 2 |
31 Dec 17 | 0 | -11 | 5 | 2 |
30 Sep 17 | 0 | -11 | 5 | 2 |
30 Jun 17 | 0 | -9 | 5 | 2 |
31 Mar 17 | 0 | -6 | 5 | 1 |
31 Dec 16 | 0 | -6 | 6 | 1 |
30 Sep 16 | 0 | -6 | 7 | 1 |
30 Jun 16 | 0 | -10 | 9 | 2 |
31 Mar 16 | 0 | -12 | 10 | 2 |
31 Dec 15 | 0 | -13 | 10 | 2 |
30 Sep 15 | 0 | -13 | 10 | 1 |
30 Jun 15 | 0 | -13 | 10 | 1 |
31 Mar 15 | 0 | -13 | 9 | 1 |
31 Dec 14 | 0 | -12 | 9 | 1 |
30 Sep 14 | 0 | -12 | 9 | 2 |
30 Jun 14 | 0 | -12 | 10 | 1 |
31 Mar 14 | 0 | -11 | 10 | 1 |
31 Dec 13 | 1 | -11 | 10 | 1 |
30 Sep 13 | 1 | -10 | 9 | 1 |
Quality Earnings: ATOS is currently unprofitable.
Growing Profit Margin: ATOS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ATOS is unprofitable, and losses have increased over the past 5 years at a rate of 13.7% per year.
Accelerating Growth: Unable to compare ATOS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATOS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: ATOS has a negative Return on Equity (-32.32%), as it is currently unprofitable.